Clinical Trial Update: uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating uCD7 CAR-T cells for relapsed or refractory CD7-positive hematologic malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• T-cell Acute Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• uCD7 CAR-T

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma | Phase 1 | Status: RECRUITING